Disease · MONDO_0005103
well-differentiated liposarcoma
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. well-differentiated liposarcoma. Diseases, record MONDO_0005103. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005103
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Other names
- ALT, WDLS, atypical lipoma, atypical lipomatous tumor, well differentiated liposarcoma of deep soft tissue
- Open Targets
Drugs3
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| RIBOCICLIB | CHEMBL3545110 | Small molecule | Phase 2 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| PALBOCICLIB | CHEMBL189963 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| BRIGIMADLIN | CHEMBL5314455 | Small molecule | Phase 1 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
Targets3
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| CDK4 | Cyclin-dependent kinase 4 | 2 | Cyclin-dependent kinase 4 inhibitor; Cyclin-dependent kinase 4/cyclin D1 inhibitor | Phase 2 | https://conductscience.org/library/genes/1019 | Drugs and targets |
| CDK6 | CDK6/cyclin D1 | 2 | CDK6/cyclin D1 inhibitor; Cyclin-dependent kinase 6 inhibitor | Phase 2 | https://conductscience.org/library/genes/1021 | Drugs and targets |
| CCND1 | CDK6/cyclin D1 | 1 | CDK6/cyclin D1 inhibitor; Cyclin-dependent kinase 4/cyclin D1 inhibitor | Phase 2 | https://conductscience.org/library/genes/595 | Drugs and targets |
Trials4
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01209598 | PD0332991 (Palbociclib) in Patients With Advanced or Metastatic Liposarcoma | Phase 2 | 90 | 2017-11-06 | Sarcoma, Liposarcoma | PALBOCICLIB | Its record names the disease | ClinicalTrials.gov |
| NCT03449381 | This Study Aims to Find the Best Dose of BI 907828 (Brigimadlin) in Patients With Different Types of Advanced Cancer (Solid Tumors) | Phase 1 | 266 | Neoplasms | BRIGIMADLIN | Its record names the disease | ClinicalTrials.gov | |
| NCT02571829 | A Phase II Study Assessing Efficacy & Safety of Ribociclib in Patients With Advanced Well/Dedifferentiated Liposarcoma | Phase 2 | 30 | Liposarcoma, Soft Tissue Sarcoma | RIBOCICLIB | Its record names the disease | ClinicalTrials.gov | |
| NCT03096912 | A Study Assessing Efficacy & Safety of Ribociclib in Patients With Advanced Well/Dedifferentiated Liposarcoma | Phase 2 | 30 | Liposarcomas, Dedifferentiated, Liposarcoma - Well Differentiated, Liposarcoma; Mixed Type, Soft-Tissue Sarcoma | RIBOCICLIB | Its record names the disease | ClinicalTrials.gov |
Comparisons in its trials1
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial |
|---|---|---|---|---|
| Palbociclib 200mg vs Palbociclib 125mg: serious adverse events | 24 of 30 | 55 of 60 | 90 | NCT01209598 |
Source Trial comparisons
Papers from its trials5
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0005103
GET https://conductscience.org/api/diseases/v1/MONDO_0005103/drugs